Lanshoeft Christian, Wolf Thierry, Walles Markus, Barteau Samuel, Picard Franck, Kretz Olivier, Cianférani Sarah, Heudi Olivier
Novartis Institutes for Biomedical Research, Drug Metabolism and Pharmacokinetics, Fabrikstrasse 14 - Novartis Campus, 4056, Basel, Switzerland; Laboratoire de Spectrométrie de Masse BioOrganique, Institut Pluridisciplinaire Hubert Curien, CNRS-Université de Strasbourg, UMR 7178, 25 rue Becquerel, 67087, Strasbourg, France.
Novartis Institutes for Biomedical Research, Drug Metabolism and Pharmacokinetics, Fabrikstrasse 14 - Novartis Campus, 4056, Basel, Switzerland.
J Pharm Biomed Anal. 2016 Nov 30;131:214-222. doi: 10.1016/j.jpba.2016.08.039. Epub 2016 Aug 31.
An increasing demand of new analytical methods is associated with the growing number of biotherapeutic programs being prosecuted in the pharmaceutical industry. Whilst immunoassay has been the standard method for decades, a great interest in assays based on liquid chromatography tandem mass spectrometry (LC-MS/MS) is evolving. In this present work, the development of a generic method for the quantitative analysis of therapeutic proteins based on human immunoglobulin G (hIgG) in rat serum is reported. The method is based on four generic peptides GPSVFPLAPSSK (GPS), TTPPVLDSDGSFFLYSK (TTP), VVSVLTVLHQDWLNGK (VVS) and FNWYVDGVEVHNAK (FNW) originating from different parts of the fraction crystallizable (Fc) region of a reference hIgG1 (hIgG1A). A tryptic pellet digestion of rat serum spiked with hIgG1A and a stable isotope labeled protein (hIgG1B) used as internal standard (ISTD) was applied prior LC-MS/MS analysis. The upper limit of quantification was at 1000μg/mL. The lower limit of quantitation was for GPS, TTP and VVS at 1.00μg/mL whereas for FNW at 5.00μg/mL. Accuracy and precision data met acceptance over three days. The presented method was further successfully applied to the quantitative analysis of other hIgG1s (hIgG1C and hIgG1D) and hIgG4-based therapeutic proteins on spiked quality control (QC) samples in monkey and rat serum using calibration standards (Cs) prepared with hIgG1A in rat serum. In order to extend the applicability of our generic approach, a bispecific-bivalent hIgG1 (bb-hIgG1) and two lysine conjugated antibody-drug conjugates (ADC1 and ADC2) were incorporated as well. The observed values on spiked QC samples in monkey serum were satisfactory with GPS for the determination of bb-hIgG1 whereas the FNW and TTP peptides were suitable for the ADCs. Moreover, comparable mean concentration-time profiles were obtained from monkeys previously dosed intravenously with ADC2 measured against Cs samples prepared either with hIgG1A in rat serum (presented approach) or with the actual ADC2 in monkey serum (conventional approach). The results of this study highlight the great flexibility of our newly developed generic approach and that the choice of the surrogate peptide still remains critical when dealing with different matrix types or modalities.
制药行业中正在推进的生物治疗项目数量不断增加,这与对新分析方法的需求日益增长相关。几十年来,免疫测定一直是标准方法,但基于液相色谱串联质谱(LC-MS/MS)的测定方法正引起人们极大的兴趣。在本研究中,报道了一种基于大鼠血清中人免疫球蛋白G(hIgG)的治疗性蛋白质定量分析通用方法的开发。该方法基于源自参考hIgG1(hIgG1A)的可结晶片段(Fc)区域不同部位的四种通用肽GPSVFPLAPSSK(GPS)、TTPPVLDSDGSFFLYSK(TTP)、VVSVLTVLHQDWLNGK(VVS)和FNWYVDGVEVHNAK(FNW)。在进行LC-MS/MS分析之前,对添加了hIgG1A和用作内标(ISTD)的稳定同位素标记蛋白(hIgG1B)的大鼠血清进行胰蛋白酶沉淀消化。定量上限为1000μg/mL。GPS、TTP和VVS的定量下限为1.00μg/mL,而FNW的定量下限为5.00μg/mL。三天内的准确度和精密度数据均符合要求。所提出的方法进一步成功应用于使用大鼠血清中hIgG1A制备的校准标准品(Cs)对猴和大鼠血清中加标的质量控制(QC)样品上的其他hIgG1(hIgG1C和hIgG1D)以及基于hIgG4的治疗性蛋白质进行定量分析。为了扩展我们通用方法的适用性,还纳入了双特异性二价hIgG1(bb-hIgG1)和两种赖氨酸缀合的抗体药物偶联物(ADC1和ADC2)。在猴血清中加标的QC样品上,对于bb-hIgG1的测定,GPS的观测值令人满意,而FNW和TTP肽适用于ADC。此外,从先前静脉注射ADC2的猴子获得的平均浓度-时间曲线与使用大鼠血清中hIgG1A制备的Cs样品(所提出的方法)或猴血清中的实际ADC2(传统方法)测量的结果相当。本研究结果突出了我们新开发的通用方法的极大灵活性,并且在处理不同基质类型或模式时,替代肽的选择仍然至关重要。